At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis
In Brief
A Phase 2 clinical trial evaluating bortezomib, cyclophosphamide, and 1 other intervention for Primary Systemic Amyloidosis. Completed, enrolled 2 participants across 1 site.
Detailed Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib, cyclophosphamide, and dexamethasone together works in treating patients with primary systemic light chain amyloidosis.
Study Details
Timeline
Interventions
1.3 mg/m\^2, by IV on days 1, 8 and 15 every 28 days
300 mg/m\^2, orally, on days 1, 8, 15 \& 22 every 28 days.
40 mg, orally, on days 1, 8, 15 \& 22 every 28 days